@article{TLCR116515,
author = {Jianjiao Ni and Zilu Zheng and Xi Yang and Xiao Chu and Yue Zhou and Yechun Pang and Hongru Chen and Silai Yu and Fei Liang and Zhengfei Zhu and Li Chu},
title = {Cadonilimab induction and consolidation for unresectable stage III non-small cell lung cancer patients receiving concurrent chemoradiation: safety run-in results of a prospective, phase II trial},
journal = {Translational Lung Cancer Research},
volume = {15},
number = {4},
year = {2026},
keywords = {},
abstract = {Concurrent chemoradiotherapy (cCRT) followed by durvalumab consolidation remains the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). However, treatment outcomes remain suboptimal. Induction immunotherapy has emerged as a potential strategy to preserve systemic immunity and improve local and distant disease control. Cadonilimab (AK104), a bispecific antibody targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), has shown promising efficacy in advanced NSCLC. This study sought to assess the safety and efficacy of cadonilimab as both induction and consolidation therapy in unresectable stage III NSCLC. We present the initial safety run-in results of the study.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/116515}
}